<code id='DA49B03EDB'></code><style id='DA49B03EDB'></style>
    • <acronym id='DA49B03EDB'></acronym>
      <center id='DA49B03EDB'><center id='DA49B03EDB'><tfoot id='DA49B03EDB'></tfoot></center><abbr id='DA49B03EDB'><dir id='DA49B03EDB'><tfoot id='DA49B03EDB'></tfoot><noframes id='DA49B03EDB'>

    • <optgroup id='DA49B03EDB'><strike id='DA49B03EDB'><sup id='DA49B03EDB'></sup></strike><code id='DA49B03EDB'></code></optgroup>
        1. <b id='DA49B03EDB'><label id='DA49B03EDB'><select id='DA49B03EDB'><dt id='DA49B03EDB'><span id='DA49B03EDB'></span></dt></select></label></b><u id='DA49B03EDB'></u>
          <i id='DA49B03EDB'><strike id='DA49B03EDB'><tt id='DA49B03EDB'><pre id='DA49B03EDB'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:94881
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Readout LOUD podcast: What to know about H5N1 bird flu
          Readout LOUD podcast: What to know about H5N1 bird flu

          Whathappenswhenacommonvirusjumpsfrombirdstocows?Andshouldwebeconcerned?Thisweekon“TheReadoutLOUD,”ST

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Vir antibody drug aimed at influenza A fails in clinical trial

          F.A.Murphy/CDCVirBiotechnologysaidThursdaythatalong-actingantibodydrugdesignedtoprotecthealthyindivi